Compugen vs Monte Rosa Therapeutics
CGEN and GLUE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGEN and GLUE compare
Compugen grew revenue faster over the last twelve months (161% versus −61.3% for Monte Rosa Therapeutics).
Compugen keeps more of each dollar of sales as profit, with a net margin of 48.6% compared with −186% at Monte Rosa Therapeutics.
Compugen scores higher on the StockData Score (12 against 7 for Monte Rosa Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGEN | GLUE |
|---|---|---|
| Size and price | ||
| Market cap | – | $799M |
| Share price | $2.10 | $9.37 |
| Change, 1 year | 25.0% | −33.8% |
| Change, 5 years | −55.4% | −52.1% |
| Beta (5Y) | 1.61 | 1.83 |
| Employees | 2 | 150 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 4 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 11.4× |
| P/B | – | 1.6× |
| FCF yield | – | −21.8% |
| Fair value | – | $8.37 |
| Margin of safety | – | −11.9% |
| Growth | ||
| Revenue growth (TTM) | 161% (better) | −61.3% |
| Revenue growth, 5Y average | 105% | – |
| Net income growth (TTM) | – | −725% |
| EPS growth (TTM) | – | −660% |
| Profitability | ||
| Gross margin | 87.3% | – |
| Operating margin | 43.1% (better) | −214% |
| Net margin | 48.6% (better) | −186% |
| FCF margin | 43.1% (better) | −248% |
| Return on equity | 50.9% (better) | −35.3% |
| Return on invested capital | 117% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.72 | 10.32 (better) |
| Altman Z-score | – | 1.63 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | – | 109% |
| Held by insiders | 0.43% | 11.5% |
| Insider net buying, 12 months | −$126K (better) | −$4.1M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.7% | 27.6% |
Go deeper
- CGEN stock overview
- CGEN income statement
- CGEN valuation and score
- GLUE stock overview
- GLUE income statement
- GLUE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.